Hyeyoung Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hyeyoung Kim has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Nam-Joon Yi
Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
17 shared publications - Kyung-Suk Suh
Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea
14 shared publications - Kwang-Woong Lee
Department of Surgery, Seoul National University Hospital, Seoul, Korea
11 shared publications - YoungRok Choi
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
10 shared publications - Kyoung Bun Lee
Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
8 shared publications - Suk Kyun Hong
Department of Surgery, Seoul National University Hospital, Seoul, Korea
6 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
Optimal strategies for pancreatic stump management in distal pancreatectomy: A network meta-analysis of randomized controlled trials
Yung Kil Kim, Sang Ho Bae, Hyeyoung Kim, Hyun Yong Lee, Seung Hee Seo, Seun Deuk Hwang, Hae Il Jung. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.26-106
- 18 August 2026
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
Open AccessOptimal strategies for pancreatic stump management in distal pancreatectomy: A network meta-analysis of randomized controlled trials
Yung Kil Kim, Sang Ho Bae, Hyeyoung Kim, Hyun Yong Lee, Seung Hee Seo, Seun Deuk Hwang, Hae Il Jung. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.26-106
- Open Access
- 1 November 2022
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 103 (5) , 271-279
Prognostic value of preoperative protein-induced vitamin K absence or antagonist II after liver resection for hepatitis B-related hepatocellular carcinoma: a nationwide multicenter study
Byun D, et al. Ann Surg Treat Res. 2022 Nov;103(5):271-279. https://doi.org/10.4174/astr.2022.103.5.271
- 1 November 2022
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 103 (5) , 271-279
Open AccessPrognostic value of preoperative protein-induced vitamin K absence or antagonist II after liver resection for hepatitis B-related hepatocellular carcinoma: a nationwide multicenter study
Byun D, et al. Ann Surg Treat Res. 2022 Nov;103(5):271-279. https://doi.org/10.4174/astr.2022.103.5.271
- 17 June 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (9) , e14011
Impact of PNPLA3 (rs738409‐G) polymorphism on post‐transplant outcomes after liver transplantation for alcohol‐related liver disease
Introduction: We aimed to evaluate the association between PNPLA3 polymorphism and post‐liver transplantation (LT) outcomes related to alcohol relapse (AR).Method: We retrospectively analyzed data from patients receiving LT for alcoholic liver disease (ALD) from 04/2014 to 12/2017. Liver‐related clinical outcomes were assessed by the gamma‐glutamyltransferase (GGT) level and alcohol‐related liver failure (ARLF). Genotyping was performed using prospectively collected DNA samples in both donors and recipients.Results: A total of 83 recipients were enrolled. Post‐LT AR occurred in 31 patients (37.3%). Thirty‐one patients (14 AR, 9 abstainers) showed elevated GGT levels, and 3 AR patients experienced ARLF. In the multivariate analysis, rs738409 G allele carrier and heavy drinking (HRAR score ≥ 4) were independent risk factors for elevated GGT levels (odds ratio [OR] = 8.69, P < .01; OR = 13.07, P = .01) and ARLF (OR = 4.52, P = .04; OR = 19.62, P = .03). Among 15 heavy AR patients, being an rs738409 G allele carrier was related to GGT elevation (P = .03) and ARLF (P = .04), but it was not related to GGT elevation in mild drinkers (n = 16) or abstainers (n = 52).Conclusion: PNPLA3 polymorphism of the recipient genotype can independently affect the post‐LT prognosis of LT patients for ALD, especially in heavy AR patients. Therefore, strong abstinence education is recommended in patients with this single nucleotide polymorphism.
- 17 June 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (9) , e14011
Impact of PNPLA3 (rs738409‐G) polymorphism on post‐transplant outcomes after liver transplantation for alcohol‐related liver disease
Introduction: We aimed to evaluate the association between PNPLA3 polymorphism and post‐liver transplantation (LT) outcomes related to alcohol relapse (AR).Method: We retrospectively analyzed data from patients receiving LT for alcoholic liver disease (ALD) from 04/2014 to 12/2017. Liver‐related clinical outcomes were assessed by the gamma‐glutamyltransferase (GGT) level and alcohol‐related liver failure (ARLF). Genotyping was performed using prospectively collected DNA samples in both donors and recipients.Results: A total of 83 recipients were enrolled. Post‐LT AR occurred in 31 patients (37.3%). Thirty‐one patients (14 AR, 9 abstainers) showed elevated GGT levels, and 3 AR patients experienced ARLF. In the multivariate analysis, rs738409 G allele carrier and heavy drinking (HRAR score ≥ 4) were independent risk factors for elevated GGT levels (odds ratio [OR] = 8.69, P < .01; OR = 13.07, P = .01) and ARLF (OR = 4.52, P = .04; OR = 19.62, P = .03). Among 15 heavy AR patients, being an rs738409 G allele carrier was related to GGT elevation (P = .03) and ARLF (P = .04), but it was not related to GGT elevation in mild drinkers (n = 16) or abstainers (n = 52).Conclusion: PNPLA3 polymorphism of the recipient genotype can independently affect the post‐LT prognosis of LT patients for ALD, especially in heavy AR patients. Therefore, strong abstinence education is recommended in patients with this single nucleotide polymorphism.
- 28 August 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13703
Different prognostic factors and strategies for early and late recurrence after adult living donor liver transplantation for hepatocellular carcinoma
Background: Some patients with hepatocellular carcinoma (HCC) recurrence after LT show good long‐term survival. We aimed to determine the prognostic factors affecting survival after recurrence and to suggest treatment strategies.Methods: Between January 2000 and December 2015, 532 patients underwent adult living donor liver transplantation (LDLT) for HCC. Among these, 92 (17.3%) who experienced recurrence were retrospectively reviewed.Results: The 1‐, 3‐, and 5‐year survival rates after recurrence were 59.5%, 23.0%, and 11.9%, respectively. In multivariate analysis, time to recurrence >6 months and surgical resection after recurrence were related to longer survival after recurrence, while multi‐organ involvement at the time of primary recurrence was related to poorer survival. We classified patients into early (≤6 months) and late (>6 months) recurrence groups. In the early recurrence group, tumor size >5 cm in the explant liver, liver as the first detected site of recurrence, and multiple organ involvement at primary recurrence were related to survival on multivariate analysis. In the late recurrence group, mammalian target of rapamycin inhibitor (mTORi) usage and multi‐organ involvement were significantly associated with the prognosis on multivariate analysis.Conclusions: Various therapeutic approaches are needed depending on the period of recurrence after LT and multiplicity of involved organs.
- 28 August 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13703
Different prognostic factors and strategies for early and late recurrence after adult living donor liver transplantation for hepatocellular carcinoma
Background: Some patients with hepatocellular carcinoma (HCC) recurrence after LT show good long‐term survival. We aimed to determine the prognostic factors affecting survival after recurrence and to suggest treatment strategies.Methods: Between January 2000 and December 2015, 532 patients underwent adult living donor liver transplantation (LDLT) for HCC. Among these, 92 (17.3%) who experienced recurrence were retrospectively reviewed.Results: The 1‐, 3‐, and 5‐year survival rates after recurrence were 59.5%, 23.0%, and 11.9%, respectively. In multivariate analysis, time to recurrence >6 months and surgical resection after recurrence were related to longer survival after recurrence, while multi‐organ involvement at the time of primary recurrence was related to poorer survival. We classified patients into early (≤6 months) and late (>6 months) recurrence groups. In the early recurrence group, tumor size >5 cm in the explant liver, liver as the first detected site of recurrence, and multiple organ involvement at primary recurrence were related to survival on multivariate analysis. In the late recurrence group, mammalian target of rapamycin inhibitor (mTORi) usage and multi‐organ involvement were significantly associated with the prognosis on multivariate analysis.Conclusions: Various therapeutic approaches are needed depending on the period of recurrence after LT and multiplicity of involved organs.
- 1 July 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (Supplement) , S20
Long-Term Outcomes after Living Liver Donation
- 1 July 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (Supplement) , S20
Long-Term Outcomes after Living Liver Donation
- 26 March 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (5) , e13244
Preformed donor‐specific antibodies do not affect the 1‐year allograft survival in living donor liver transplantation
The effect of preformed donor‐specific antibodies (DSAs) on liver transplantation (LT) remains unclear, especially in the field of living donorLT(LDLT). Herein, we evaluated the prevalence of preformedDSAs and their effect on graft outcome inLDLTin the first year following surgery. Using the Luminex®Single Antigen assay, we analyzed the preoperative sera of 61 adultLDLTrecipients between 2014 and 2015. Clinical outcomes and pathologic findings including complement component 4d (C4d) expression in the first year afterLTwere retrospectively reviewed. Regardless of the class ofDSA,DSAs with mean fluorescence intensity (MFI) ≥1000 were defined as positive and preformedDSAwithMFI≥5000 was defined as strongly positive. Fifteen patients (24.6%) had preformedDSAs, and 8 patients (13.1%) showed strongly positive preformedDSAs. Among 15DSApositive patients, 2 (13.3%) showed persistentDSAs afterLDLT. No de novoDSAs were noted in patients without preformedDSAs. PreformedDSAs were not related to graft dysfunction, laboratory values, or C4d expression or other pathologic findings in the first year ofLDLT. In conclusion, preformedDSAs persisted during follow‐up in 13.3% of cases and did not have adverse effect on histologic or clinical outcomes in the first year ofLDLT.
- 26 March 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (5) , e13244
Preformed donor‐specific antibodies do not affect the 1‐year allograft survival in living donor liver transplantation
The effect of preformed donor‐specific antibodies (DSAs) on liver transplantation (LT) remains unclear, especially in the field of living donorLT(LDLT). Herein, we evaluated the prevalence of preformedDSAs and their effect on graft outcome inLDLTin the first year following surgery. Using the Luminex®Single Antigen assay, we analyzed the preoperative sera of 61 adultLDLTrecipients between 2014 and 2015. Clinical outcomes and pathologic findings including complement component 4d (C4d) expression in the first year afterLTwere retrospectively reviewed. Regardless of the class ofDSA,DSAs with mean fluorescence intensity (MFI) ≥1000 were defined as positive and preformedDSAwithMFI≥5000 was defined as strongly positive. Fifteen patients (24.6%) had preformedDSAs, and 8 patients (13.1%) showed strongly positive preformedDSAs. Among 15DSApositive patients, 2 (13.3%) showed persistentDSAs afterLDLT. No de novoDSAs were noted in patients without preformedDSAs. PreformedDSAs were not related to graft dysfunction, laboratory values, or C4d expression or other pathologic findings in the first year ofLDLT. In conclusion, preformedDSAs persisted during follow‐up in 13.3% of cases and did not have adverse effect on histologic or clinical outcomes in the first year ofLDLT.
- 31 December 2017
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 31 (4) , 193-199
Initiating Liver Transplantation at a Public Hospital in Korea
Lee DH, et al. J Korean Soc Transplant. 2017 Dec;31(4):193-199. https://doi.org/10.4285/jkstn.2017.31.4.193
- 31 December 2017
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 31 (4) , 193-199
Initiating Liver Transplantation at a Public Hospital in Korea
Lee DH, et al. J Korean Soc Transplant. 2017 Dec;31(4):193-199. https://doi.org/10.4285/jkstn.2017.31.4.193
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (9) , 1385-1395
Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo
Mussin N, et al. J Korean Med Sci. 2017 Sep;32(9):1385-1395. https://doi.org/10.3346/jkms.2017.32.9.1385
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (9) , 1385-1395
Open AccessSirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo
Mussin N, et al. J Korean Med Sci. 2017 Sep;32(9):1385-1395. https://doi.org/10.3346/jkms.2017.32.9.1385
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (6) , 919-925
Korean Patients Undergoing Deceased Donor Liver Transplantation for Alcoholic Liver Disease Have Non-Inferior Survival Outcomes than for Hepatitis B Virus: a Real-World Experience without Minimum Abstinence before Transplantation
Hong SK, et al. J Korean Med Sci. 2017 Jun;32(6):919-925. https://doi.org/10.3346/jkms.2017.32.6.919
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (6) , 919-925
Open AccessKorean Patients Undergoing Deceased Donor Liver Transplantation for Alcoholic Liver Disease Have Non-Inferior Survival Outcomes than for Hepatitis B Virus: a Real-World Experience without Minimum Abstinence before Transplantation
Hong SK, et al. J Korean Med Sci. 2017 Jun;32(6):919-925. https://doi.org/10.3346/jkms.2017.32.6.919
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (2) , 315-320
False Positive Diagnosis of Hepatocellular Carcinoma in Liver Resection Patients
Lee H, et al. J Korean Med Sci. 2017 Feb;32(2):315-320. https://doi.org/10.3346/jkms.2017.32.2.315
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (2) , 315-320
Open AccessFalse Positive Diagnosis of Hepatocellular Carcinoma in Liver Resection Patients
Lee H, et al. J Korean Med Sci. 2017 Feb;32(2):315-320. https://doi.org/10.3346/jkms.2017.32.2.315